Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, is announcing that people who are suffering from fibromyalgia pain but do not want to risk addiction to an opioid are closer to a new option for treatment. According to the announcement, the company announced positive Phase 3 study results for its non-opioid investigational drug candidate Tonmya or TNX-102 SL in late December. The results showed that Tonmya lowered the characteristic widespread pain in fibromyalgia, indicating that it could potentially be the first in a new class of painkillers to be approved for use in fibromyalgia. In addition, the experimental medicine improved sleep and fatigue in fibromyalgia. Tonix intends to submit a New Drug Application (“NDA”) with the FDA in the second half of the year and expects a decision in 2025.
Additionally, Tonix is featured in an FN Media Group News Commentary. The commentary covered Tonix’s recent news, including the announcement that the company has engaged Rho, Inc., a global contract research organization (“CRO”), to support its preparation and planned submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration. The NDA will seek FDA approval for Tonmya(TM) (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. The commentary also highlighted a recent key opinion leader (“KOL”) webinar held to discuss the positive Phase 3 data of Tonmya for the management of fibromyalgia and the path to file for FDA approval in the second half of 2024.
To view the full press releases, visit https://ibn.fm/t9IVu and https://ibn.fm/GQzjA
About Tonix Pharmaceuticals Holding Corp.
Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (“NDA”) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and topline results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (“PWS”). TNX-2900 has been granted Orphan Drug designation by the FDA and an investigational new drug (“IND”) application has been cleared to support a Phase 2 study in PWS patients. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (“CD40L” or “CD154”) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-801 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (“NIH”), National Institute of Allergy and Infectious Diseases (“NIAID”) Project NexGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R) (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. For more information about Tonix, visit www.tonixpharma.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN